NeuroMetrix (NURO) Total Debt to Capital

NeuroMetrix, Inc. (NURO) - corporate logo

NeuroMetrix, Inc. (NURO) is expanding the availability of Quell pain management systems through pharmacies and digital monitoring. This chart on GURU.Markets for the separate_debt_total_eq metric shows 0.01, while weak pricing power due to limited insurance coverage makes demand sensitive. The company generates revenue from the sale of neurostimulators and diagnostic equipment for clinics and individuals with neuropathy.

NURO: neurometrix.com Debt to Equity Ratio 07/04/2022 - 05/11/2025

Analytical breakdowns for NeuroMetrix, Inc.

- price and consensus price forecast:
Price Chart NeuroMetrix|NURO - Consensus Target
- market capitalization details:
Market Capitalization NeuroMetrix|NURO - Total Enterprise Value
- book capitalization indicators:
Book Value per Share NeuroMetrix|NURO - Accounting Capitalization|Market Capitalization to Book Value Ratio neurometrix.com|NURO - Company Total Asset Base
- issuer credit burden and liquidity indicators:
Total Debt to Capital NeuroMetrix, Inc.|NURO - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital NeuroMetrix, Inc.|NURO - Company Aggregate Debts|Debt to Book Capitalization Ratio NeuroMetrix|NURO - Company Long-Term Debt|Company Current Liabilities NeuroMetrix|Quick Ratio neurometrix.com
- earnings and valuation multiples information:
NURO - Net Financial Result
Basic company analysis:NURO, NeuroMetrix
Finished products of NeuroMetrix Corporation

The Debt-to-Equity ratio measures the proportion of borrowed funds relative to shareholders' equity, allowing investors to assess financial leverage and the balance sheet's resilience to changes in Fed rates. Analyzing the balance between debt and equity helps filter out market noise to determine whether NeuroMetrix, Inc. (NURO) possesses sufficient resources to scale Quell device sales through pharmacy chains and implement digital monitoring platforms.

Key competitors

Debt to Equity Intuitive|Total Debt to Equity Ratio Danaher Corporation (DHR)|Total Debt to Capital BDX|STE - Debt to Capital|Total Debt to Capital WST (West Pharmaceutical Services)|BAX: Debt to Equity Ratio|Masimo - Total Debt to Capital|Total Debt to Capital Coefficient Stevanato Group SpA STVN|TFX: Total Debt to Capital|Total Debt to Equity Ratio Merit Medical Corp|NVST (Envista Holdings) - Total Debt to Capital|Total Debt to Capital icumed.com|Debt to Equity Dentsply Sirona (XRAY)|Debt to Equity LMAT (LeMaitre Vascular Inc)|AtriCure Corp - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio STAA|ChromaDex Corp. - Total Debt to Capital|Total Debt to Capital Coefficient zimvie.com ZIMV|AngioDynamics (ANGO) - Debt to Equity|Debt to Equity Ratio CERS|Debt to Equity Alpha Teknova Inc|Monogram Orthopedics Inc. (MGRM) - Total Debt to Capital Coefficient|Total Debt to Equity Ratio STSS (Sharps Technology, Inc.)|Aggregate Debt to Capital INFU|Debt to Equity Utah Medical Products, Inc. UTMD|All Debt to Shareholders' Equity Ratio KRMD|NYXH: Total Debt to Equity Ratio|MBOT - Total Debt to Capital|Pro-Dex, Inc. (PDEX) - Debt to Equity|Total Debt to Equity Ratio zentek.com|ELUT (Elutia) - Total Debt to Capital|Debt to Capital Milestone Scientific Inc MLSS|Debt to Equity NEXGEL, Inc (NXGL)|retractable.com - Debt to Equity Ratio|Harvard Bioscience, Inc. - Total Debt to Equity Ratio|Aggregate Debt to Capital FEMY (femasys.com)|MHUA - Debt to Equity|Total Debt to Capital Coefficient Predictive Oncology POAI|callanjmb.com (CJMB) - Debt to Equity|Debt to Equity Ratio ATRI